The effect of mycophenolate mofetil on platelet function

Area of Science:

• Hematology
• Pharmacology
• Immunology

Background:

• Mycophenolate mofetil (MMF) is used to increase platelet counts in primary immune thrombocytopenia.
• Concerns exist regarding MMF's potential to inhibit collagen-induced platelet aggregation, raising bleeding risk.
• In vitro evaluation of MMF's effect on platelet function is crucial for understanding its safety profile.

Purpose of the Study:

• To investigate the in vitro effects of Mycophenolate mofetil (MMF) and its active metabolite, mycophenolic acid (MPA), on platelet function.
• To assess the impact of MMF and MPA on platelet aggregation induced by various agonists.
• To determine if MMF or MPA influence platelet activation markers and receptor expression.

Main Methods:

• Blood samples from healthy donors were incubated with MMF or MPA at clinically relevant concentrations.
• Platelet aggregation was measured using flow cytometry and 96-well light transmission aggregometry (LTA).
• Platelet activation markers (P-selectin, active GPIIb/IIIa) and receptor expression (GPVI) were assessed via flow cytometry.

Main Results:

• MMF and MPA did not significantly alter platelet aggregation with most agonists.
• A minor, yet significant, decrease in collagen-induced platelet aggregation was observed with MMF and MPA via flow cytometry, but not LTA.
• MPA significantly reduced the relative surface expression of the collagen receptor GPVI.

Conclusions:

• Mycophenolate mofetil (MMF) and mycophenolic acid (MPA) exhibit only a minor inhibitory effect on collagen-induced platelet aggregation in vitro.
• The observed effect on collagen-induced aggregation was modest and not consistently detected across different measurement methods.
• MPA's reduction in GPVI receptor expression may underlie the minor impact on collagen-induced platelet function.